Table 2. Administered treatments and therapeutic needs.
Total (n = 318) | Survivors (n = 271) | Non-survivors (n = 47) | P value | |
---|---|---|---|---|
Need for oxygen supplementation | 259 (81.4%) | 215 (79.3%) | 44 (93.6%) | 0.024 |
Needed high oxygen volume | 74 (23.9%) | 38 (14.4%) | 36 (78.3%) | <0.001 |
Mechanical Assisted Ventilation (non-invasive) | ||||
CPAP | 3 (0.943%) | 2 (0.743%) | 1 (2.22%) | 0.372 |
High flux Oxygen | 27 (8.49%) | 18 (6.69%) | 9 (20%) | 0.007 |
Entered Intensive Care | 37 (11.8%) | 24 (8.96%) | 13 (28.3%) | 0.001 |
Mechanical Assisted Ventilation (invasive) | 25 (7.91%) | 12 (4.44%) | 13 (28.3%) | <0.001 |
Hydroxychloroquine | 297 (93.4%) | 257 (94.8%) | 40 (85.1%) | 0.022 |
Azithromycin | 281 (88.6%) | 244 (90.4%) | 37 (78.7%) | 0.042 |
Lopinavir/Ritonavir | 209 (65.7%) | 180 (66.4%) | 29 (61.7%) | 0.618 |
Interferon | 37 (11.7%) | 27 (10%) | 10 (21.3%) | 0.045 |
High Dose Corticosteroids PT | 64 (20.1%) | 60 (22.1%) | 4 (8.51%) | 0.031 |
Low Dose Corticosteroids | 68 (21.4%) | 57 (21%) | 11 (23.4%) | 0.702 |
Tozilizumab | 24 (7.59%) | 17 (6.32%) | 7 (14.9%) | 0.066 |
Immunoglobulins | 3 (0.943%) | 3 (1.11%) | 0 (0%) | 1 |
Anakinra | 2 (0.629%) | 2 (0.738%) | 0 (0%) | 1 |
Vitamin D Supplementation | 37 (11.6%) | 36 (13.3%) | 1 (2.13%) | 0.025 |
Anticoagulants: prophylactic dose | 233 (73.3%) | 200 (74.6%) | 33 (70.2%) | 0.589 |
Anticoagulants: intermediate dose | 24 (7.55%) | 22 (8.18%) | 2 (4.26%) | 0.551 |
Anticoagulants: full dose | ||||
DOACs | 5 (1.57%) | 5 (1.86%) | 0 (0%) | 1 |
LMWH | 83 (26.1%) | 61 (22.7%) | 22 (46.8%) | 0.001 |
CPAP, continuous positive airway pressure. High Dose Corticosteroids PT, high dose corticosteroids pulse therapy. DOACs, direct-acting oral anticoagulants. LMWH, low-molecular-weight-heparin. Numerical variables are presented as mean (standard deviation). Categorical variables are presented as total number with percentages. P values were computed with a Student t-test (numerical variables) or Fisher’s exact test (categorical variables).